Merck & Co Inc (MRK)

65.79
NYSE : Health Care
Prev Close 65.79
Day Low/High 0.00 / 0.00
52 Wk Low/High 58.29 / 66.80
Avg Volume 7.79M
Exchange NYSE
Shares Outstanding 2.73B
Market Cap 179.87B
EPS 1.40
P/E Ratio 35.65
Div & Yield 1.88 (2.90%)

Latest News

Cramer: Got the Apple-FANG Blues? Look for a Rotation

Cramer: Got the Apple-FANG Blues? Look for a Rotation

There's one going on now.

Where Are the Missing Stocks?

Fewer stocks have been making new highs lately.

Merck Announces Findings From Phase 3 Study Of KEYTRUDA® (pembrolizumab), Compared To Standard Of Care, In Patients With Previously Treated Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Merck Announces Findings From Phase 3 Study Of KEYTRUDA® (pembrolizumab), Compared To Standard Of Care, In Patients With Previously Treated Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the phase 3 KEYNOTE-040 trial investigating KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, compared to...

Merck's KEYTRUDA® (pembrolizumab) Continues To Show Overall Survival Benefit Over Chemotherapy With Nearly Two Years Follow-Up In Previously Treated Patients With Advanced Urothelial Carcinoma, Post-Platinum Failure

Merck's KEYTRUDA® (pembrolizumab) Continues To Show Overall Survival Benefit Over Chemotherapy With Nearly Two Years Follow-Up In Previously Treated Patients With Advanced Urothelial Carcinoma, Post-Platinum Failure

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated results from the phase 3 KEYNOTE-045 trial evaluating KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in...

Progression-Free Survival Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (pembrolizumab) Underscore Durability Of Response In Patients With Advanced Melanoma

Progression-Free Survival Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (pembrolizumab) Underscore Durability Of Response In Patients With Advanced Melanoma

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating epacadostat, Incyte's...

Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed And Carboplatin (pem/carbo) Demonstrated Continued Benefit In Overall Response Rates And Progression-Free Survival Compared To Pem/Carbo Alone In Patients With First-Line Nonsquamous NSCLC

Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed And Carboplatin (pem/carbo) Demonstrated Continued Benefit In Overall Response Rates And Progression-Free Survival Compared To Pem/Carbo Alone In Patients With First-Line Nonsquamous NSCLC

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated results from Cohort G of the phase 2 KEYNOTE-021 trial investigating KEYTRUDA ® (pembrolizumab), the company's anti-PD-1...

Updated Data For Merck's KEYTRUDA® (pembrolizumab) In Patients With Advanced Gastric Cancer Across Treatment Settings To Be Presented At ESMO 2017 Congress

Updated Data For Merck's KEYTRUDA® (pembrolizumab) In Patients With Advanced Gastric Cancer Across Treatment Settings To Be Presented At ESMO 2017 Congress

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of KEYTRUDA ®...

Merck To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Merck To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Merck To Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership In Immuno-Oncology

Merck To Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership In Immuno-Oncology

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Rigontec today announced that Merck will acquire Rigontec.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Certain Patients With Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Certain Patients With Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, for the treatment of certain...

New And Updated Data For KEYTRUDA® (pembrolizumab) From Merck's Extensive Immuno-Oncology Program To Be Presented At The ESMO 2017 Congress

New And Updated Data For KEYTRUDA® (pembrolizumab) From Merck's Extensive Immuno-Oncology Program To Be Presented At The ESMO 2017 Congress

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that studies involving KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in 12 different types of cancer will be...

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

America's biggest hedge funds are worth over $6 trillion combined, and here are the most common stocks they're selling.

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts

Cramer reflects on why keeping cash on hand is a good thing and also explores the lack of any conviction to the downside.

European Pharma Companies Slip on MS Pricing Probe

European Pharma Companies Slip on MS Pricing Probe

House Democrats start probe into MS drug prices

CEOs Are Failing to Act Like Real Leaders In Taking Weak Stand Against Trump

CEOs Are Failing to Act Like Real Leaders In Taking Weak Stand Against Trump

CEOs were slow to respond even after Merck CEO Ken Frazier was the first executive to exit President Donald Trump's manufacturing council.

Trump Hasn't Sunk Infrastructure Stocks...Yet

Trump Hasn't Sunk Infrastructure Stocks...Yet

Avoid GE.

When Merck's CEO Resigned From Trump's Councils, He Did What Had to Be Done

When Merck's CEO Resigned From Trump's Councils, He Did What Had to Be Done

He showed true leadership. Other executives should try to be more like him.

Why You Should Clamp It Shut with Political Opinions at the Office

Why You Should Clamp It Shut with Political Opinions at the Office

Amid the current tenuous political climate, co-workers face many hurdles as they discuss the reactions of elected officials and CEOs to recent incidences of racism and violence.

Cramer: August Finally Arrives

Cramer: August Finally Arrives

There are plenty of reasons for the selloff, not the least of which is White House chaos.

LYNPARZA Receives Additional And Broad Approval In The U.S. For Ovarian Cancer

LYNPARZA Receives Additional And Broad Approval In The U.S. For Ovarian Cancer

AstraZeneca and Merck & Co., Inc.

In Trump CEO Council Exodus, Early Movers Stand Out

In Trump CEO Council Exodus, Early Movers Stand Out

Some CEOs quit Trump's advisory councils before they were disbanded on Wednesday. Most waited until after.

TheStreet Quant Rating: B+ (Buy)